Trump Bought Tobacco Stocks and Raked In Industry Donations as FDA Eased Standards - Top-Institutions - MDSpire

Trump Bought Tobacco Stocks and Raked In Industry Donations as FDA Eased Standards

Trump’s tobacco investments and industry donations coincided with FDA moves that benefited major nicotine companies.

  • By

  • Darius Tahir

  • June 11, 2026

  • 9 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins Bloomberg School of Public Health
    Johns Hopkins Bloomberg School of Public Health

    Baltimore, Maryland

    Key Differentiators

    • Public Health
    • Tobacco Control

  • #2

    University of California, San Francisco
    University of California, San Francisco

    San Francisco, California

    Key Differentiators

    • Public Health
    • Tobacco Research

  • #3

    National Institutes of Health
    National Institutes of Health

    Bethesda, Maryland

    Key Differentiators

    • Public Health
    • Medical Research

  • #4

    National Cancer Institute
    National Cancer Institute

    Bethesda, Maryland

    Key Differentiators

    • Cancer Research
    • Public Health

  • #5

    U.S. Food and Drug Administration
    U.S. Food and Drug Administration

    Silver Spring, Maryland

    Key Differentiators

    • Public Health
    • Regulatory Affairs

Original Source(s)

Trump Bought Tobacco Stocks and Raked In Industry Donations as FDA Eased Standards

  • by Darius Tahir

  • June 11, 2026

Related Content

AI Drafts Cut Radiograph Reporting Time

Prospective cohort study found faster documentation, with no statistically significant difference in peer-reviewed report quality

Good outcome after drowning with prolonged resuscitation and secondary pediatric acute respiratory distress syndrome (pARDS) requiring extra-corporeal-membrane-oxygenation (ECMO) – A special case in comparison to the single-center local 10-year experience in pediatric drowning

Sex Disparities May Persist in CF Despite Modulators

Review findings suggested female patients with cystic fibrosis may continue to experience worse pulmonary outcomes despite highly effective modulator therapy